O Keefe Stevens Advisory Inc. Has $5.93 Million Holdings in Perrigo Company plc $PRGO

O Keefe Stevens Advisory Inc. grew its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 6.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 221,859 shares of the company’s stock after purchasing an additional 13,146 shares during the period. Perrigo comprises 1.7% of O Keefe Stevens Advisory Inc.’s holdings, making the stock its 20th largest holding. O Keefe Stevens Advisory Inc.’s holdings in Perrigo were worth $5,928,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in PRGO. Price T Rowe Associates Inc. MD lifted its holdings in shares of Perrigo by 41.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,073,026 shares of the company’s stock worth $310,488,000 after acquiring an additional 3,227,487 shares during the period. Millennium Management LLC raised its stake in shares of Perrigo by 5,198.0% during the first quarter. Millennium Management LLC now owns 2,052,599 shares of the company’s stock valued at $57,555,000 after acquiring an additional 2,013,856 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Perrigo by 126.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after buying an additional 647,982 shares during the period. Bahl & Gaynor Inc. increased its position in shares of Perrigo by 40.7% during the first quarter. Bahl & Gaynor Inc. now owns 2,146,352 shares of the company’s stock worth $60,184,000 after buying an additional 621,155 shares during the period. Finally, Sound Shore Management Inc. CT increased its position in shares of Perrigo by 23.1% during the first quarter. Sound Shore Management Inc. CT now owns 3,285,167 shares of the company’s stock worth $92,116,000 after buying an additional 616,387 shares during the period. Institutional investors own 95.91% of the company’s stock.

Insider Buying and Selling at Perrigo

In other news, EVP Robert Willis purchased 1,488 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was bought at an average cost of $24.10 per share, for a total transaction of $35,860.80. Following the acquisition, the executive vice president directly owned 41,939 shares of the company’s stock, valued at $1,010,729.90. This represents a 3.68% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Geoffrey M. Parker purchased 4,375 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were purchased at an average price of $22.97 per share, with a total value of $100,493.75. Following the completion of the acquisition, the director directly owned 33,287 shares in the company, valued at $764,602.39. The trade was a 15.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 10,118 shares of company stock valued at $232,699. Insiders own 0.70% of the company’s stock.

Perrigo Price Performance

Shares of NYSE:PRGO opened at $22.52 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81. Perrigo Company plc has a 12 month low of $20.51 and a 12 month high of $30.93. The stock has a market cap of $3.10 billion, a P/E ratio of -38.83 and a beta of 0.43. The company has a 50 day moving average of $23.26 and a 200 day moving average of $25.40.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.02). Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the firm earned $0.53 EPS. Perrigo’s quarterly revenue was down .9% on a year-over-year basis. As a group, sell-side analysts forecast that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 16th. Stockholders of record on Friday, August 29th were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 5.2%. The ex-dividend date was Friday, August 29th. Perrigo’s payout ratio is presently -200.00%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. reduced their price target on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Perrigo in a research note on Saturday, September 27th. Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Sunday, September 28th. Finally, Canaccord Genuity Group lowered their price objective on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Perrigo has an average rating of “Hold” and an average price target of $34.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.